Emcure Pharmaceuticals Ltd Cash Flow-to-Debt Ratio
Emcure Pharmaceuticals Ltd cash flow-to-debt ratio. Emcure Pharmaceuticals Ltd (EMCURE) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of Rs2.56 Billion could theoretically repay 0% of its total liabilities (Rs45.09 Billion) in one year. Check Emcure Pharmaceuticals Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Emcure Pharmaceuticals Ltd (2022–2026)
Cash flow-to-debt ratio of Emcure Pharmaceuticals Ltd from 2022 to 2026. Historical debt coverage capacity for Emcure Pharmaceuticals Ltd across 5 annual periods. Check Emcure Pharmaceuticals Ltd (EMCURE) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Emcure Pharmaceuticals Ltd Cash Flow-to-Debt Ratio by Year (2022–2026)
Emcure Pharmaceuticals Ltd cash flow-to-debt ratio by year from 2022 to 2026. Year-by-year debt coverage analysis for Emcure Pharmaceuticals Ltd. For the full cash flow conversion analysis, see cash flow conversion of Emcure Pharmaceuticals Ltd.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.18x | Rs8.51 Billion | Rs46.36 Billion | ▼ -22.6% |
| 2025 | 0.24x | Rs8.52 Billion | Rs35.91 Billion | ▲ +1.3% |
| 2024 | 0.23x | Rs10.97 Billion | Rs46.84 Billion | ▲ +26.2% |
| 2023 | 0.19x | Rs7.47 Billion | Rs40.23 Billion | ▼ -4.6% |
| 2022 | 0.19x | Rs7.68 Billion | Rs39.49 Billion | — |